A detailed history of Sovran Advisors, LLC transactions in Galectin Therapeutics Inc stock. As of the latest transaction made, Sovran Advisors, LLC holds 199,830 shares of GALT stock, worth $267,772. This represents 0.04% of its overall portfolio holdings.

Number of Shares
199,830
Previous 186,014 7.43%
Holding current value
$267,772
Previous $214 Million 28.91%
% of portfolio
0.04%
Previous 0.03%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

Apr 24, 2025

BUY
$1.1 - $1.76 $15,197 - $24,316
13,816 Added 7.43%
199,830 $276 Million
Q4 2024

Jan 29, 2025

BUY
$0.87 - $3.0 $161,832 - $558,042
186,014 New
186,014 $214 Million

Others Institutions Holding GALT

About GALECTIN THERAPEUTICS INC


  • Ticker GALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,426,000
  • Market Cap $79.6M
  • Description
  • Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...
More about GALT
Track This Portfolio

Track Sovran Advisors, LLC Portfolio

Follow Sovran Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sovran Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sovran Advisors, LLC with notifications on news.